Curanex Pharmaceuticals Inc Regains Nasdaq Compliance After Reverse Split

What Happened
Curanex Pharmaceuticals Inc announced it has regained compliance with Nasdaq Listing Rule 5550(a)(2) following a 1-for-20 reverse stock split. The Company was previously notified on November 5, 2025 that it failed to maintain the $1.00 minimum bid price. The 1-for-20 reverse split was effected on August 20, 2026, and on September 3, 2026 Nasdaq notified Curanex that the company’s closing bid price was $1.00 or greater for the last 10 consecutive business days (August 20, 2026 through September 2, 2026). The Nasdaq matter is now closed.

Key Details

• Nasdaq rule: Listing Rule 5550(a)(2) requires a $1.00 minimum closing bid.
• Reverse split: Company effected a 1-for-20 reverse stock split effective August 20, 2026.
• Nasdaq determination: On September 3, 2026 Nasdaq confirmed the company met the $1.00 bid requirement for 10 consecutive business days (Aug 20–Sep 2, 2026).
• Prior notice: Company was first notified of noncompliance on November 5, 2025.

Why It Matters
Regaining compliance means Curanex is no longer at risk of delisting from The Nasdaq Capital Market for the specific minimum bid-price deficiency referenced. The reverse split changed the number of outstanding shares (one new share for each twenty previously held), which directly affected the per-share price history used to determine compliance. Investors should note the company’s Nasdaq listing status is now reported as compliant in this filing.